Connect
MJA
MJA

New surgical technology: do we know what we are doing?

Guy J Maddern
Med J Aust 2015; 202 (8): 400-401. || doi: 10.5694/mja15.00329
Published online: 4 May 2015

How can we best protect patients while making progress?

The pace of development in new surgical procedures and technologies continues to accelerate, driven in part by manufacturers, surgeons and community expectations. Despite regulatory bodies such as the Therapeutic Goods Administration (TGA), new devices can enter the market with little or no evidence of their effectiveness, and even their safety can be poorly evaluated. The withdrawal of the DePuy Orthopaedics articular surface replacement hip prosthesis illustrates the difficulty in anticipating the unintended problems with a joint prosthesis that superficially appeared to be little different from hundreds of others already available on the market.1

Innovation is not well regulated

While the TGA attempts to assess devices, the evidence base necessary for determining their durability in human use is rarely available or is inadequate. The introduction of new procedures is even less regulated. If a completely new procedure is developed and a Medicare item number is sought, then the Medical Services Advisory Committee2 would usually assess its merits; however, this is not required in the public health system.

Of greater concern is the ability to use existing Medicare descriptors to cover new procedures. This occurred with the introduction of laparoscopic cholecystectomy in 1991 and enabled an untested new procedure to be introduced without approval, oversight or training. The subsequent outcry prompted the federal government, in partnership with the Royal Australasian College of Surgeons, to establish the Australian Safety and Efficacy Register of New Interventional Procedures – Surgical (ASERNIP-S) to evaluate the evidence for new devices or procedures and to report to surgeons, patients, government and hospitals on their evidence base and training implications.3

In 2006, ASERNIP-S evaluated three endoscopic antireflux procedures and found that evidence to support their use was lacking. Despite this, they were taken up by enthusiastic practitioners — surgeons as well as gastroenterologists. They have now completely disappeared from practice. Few reports of their failure have appeared, yet thousands of patients were subjected to these now-abandoned interventions.4

In recent years, hospitals have started to play a greater role in credentialling surgeons for procedures, and committees often exist to evaluate new procedures that are introduced into a health care facility. While an admirable principle, the practice is often flawed. New surgical approaches using existing technologies, such as laparoscopic hernia repair or laparoscopic liver resection, can be introduced into operating theatres at the discretion of the surgeon. Unless the ethical imperative to notify the institution is clear and policed, this practice may continue.

The introduction of robotic-assisted surgery for prostate operations has been widely debated.5 However, the same discussion and rigour has not been applied to robotic assistance in ear, nose and throat, gynaecological and colorectal surgery. Indeed, it is even now being used in thyroid surgery with limited evidence.6

The IDEAL recommendations

The problem of the introduction of new surgical technology and procedures has been addressed by the IDEAL recommendations.7 This concept does not view surgical development as different from non-surgical advances. The recommendations involve suggestions for the five stages of evaluating new surgical procedures — innovation, development, exploration, assessment and long-term (or surveillance) stages. Innovation will apply to interventions such as stem cell-based tracheal transplantation for tracheal stenosis.8 Exploration may apply to single-incision laparoscopy, with long-term studies being directed at procedures such as surgery for morbid obesity.8

IDEAL encourages full reporting and staged introduction of new surgical technologies so that the disasters of the past can be avoided and new lessons can be learnt quickly and disseminated. Prospective databases and registries for new procedures and techniques will allow monitoring of early as well as late and rare outcomes.

Patients are vital to progress

It is difficult for patients to provide full and informed consent for a new or innovative procedure, as results and outcomes are lacking. Preferably, the effectiveness of such uncertain new interventions would be established through ethically constructed and approved trials from which, hopefully, outcome data would be reported to the wider medical community. The participation of patients who have undergone a full and informed consent process is vital to making progress with surgical improvements and breakthroughs.

However, individual practitioners' enthusiasm for or belief in a new operation should not expose patients to oversold, poorly evaluated interventions. Surgical randomised controlled trials are difficult to perform, but they are possible. There are very few examples of operations that cannot be carefully evaluated following the IDEAL recommendations.9 Usually, there are alternative established approaches that provide other avenues for patients who are unwilling to be included in research studies.

Surgeons have a responsibility to innovate, stay up-to-date and retrain, primarily for the benefit of their patients. Guidelines, processes and regulations exist and should be embraced. Do we really know the place of innovative technologies and practices that are already in use — for example, duodenal sleeve technology,10 peritonectomy,11 robotic thyroid surgery5 or mitral clip technology?12 If not, how carefully and ethically are they being introduced into mainstream practice?


Provenance: Commissioned; externally peer reviewed.

  • Guy J Maddern

  • University of Adelaide, Adelaide, SA.


Competing interests:

No relevant disclosures.

  • 1. Australian Government, Department of Health, Therapeutic Goods Administration. Recall of DePuy Orthopaedics ASR hip replacement device. Behind the News; 16 May 2011. https://www.tga.gov.au/behind-news/recall-depuy-orthopaedics-asr-hip-replacement-device (accessed Mar 2015).
  • 2. Medical Services Advisory Committee. Guidelines for the assessment of diagnostic technologies. Aug 2005. http://www.health.gov.au/internet/msac/publishing.nsf/Content/D81BE529B98B3DB6CA2575AD0082FD1B/$File/Guidelines%20for%20the%20assessment%20of%20diagnostic%20technologies%20Sept%202005.pdf (accessed Mar 2015).
  • 3. Maddern G. The Australian Safety and Efficacy Register of New Interventional Procedures – Surgical (ASERNIP-S) assesses new surgeries. Aust Health Rev 2004; 28: 143-144.
  • 4. Chen D, Barber C, McLoughlin P, et al. Systematic review of endoscopic treatments for gastro-oesophageal reflux disease. Br J Surg 2009; 96: 128-136.
  • 5. Thavaneswaran P, Richardson C, Humphreys K, Maddern G. ASERNIP-S Report No. 75. Robotic-assisted surgery for urological, cardiac and gynaecological procedures. Adelaide: ASERNIP-S, May 2009. http://www.surgeons.org/media/299238/RPT_2009-12-09_Robotic-assisted_Surgery.pdf (accessed Apr 2015).
  • 6. Australia and New Zealand Horizon Scanning Network. Horizon scanning technology prioritising summary. Robotic-assisted endoscopic thyroidectomy. Nov 2009. http://www.horizonscanning.gov.au/internet/horizon/publishing.nsf/Content/A21BB57C2AA8FA71CA2575AD0080F3DF/$File/PS%20robot%20assisted%20thyroidectomy.pdf (accessed Mar 2015).
  • 7. McCulloch P, Altman DG, Campbell WB, et al. No surgical innovation without evaluation: the IDEAL recommendations. Lancet 2009; 374: 1105-1112.
  • 8. McCulloch P, Cook JA, Altman DG, et al. IDEAL framework for surgical innovation 1: the idea and development stages. BMJ 2013; 346: f3012.
  • 9. Barkun JS, Aronson JK, Feldman LS, et al. Evaluation and stages of surgical innovations. Lancet 2009; 374: 1089-1096.
  • 10. Koehestanie P, de Jonge C, Berends FJ, et al. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicentre randomized controlled trial. Ann Surg 2014; 260: 984-992.
  • 11. Weber T, Roitman M, Link KH. Current status of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Clin Colorectal Cancer 2012; 11: 167-176.
  • 12. Boekstegers P, Hausleiter J, Baldus S, et al; Germany Society of Cardiology Working Group on Interventional Cardiology Focus Group on Interventional Mitral Valve Therapy. Percutaneous interventional mitral regurgitation treatment using the Mitra-Clip system. Clin Res Cardiol 2014; 103: 85-96.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.